Intuitive Surgical (ISRG) Stock
Leader in robotic surgery with high margin recurring revenue. Here's the price, business snapshot, and what's worth knowing about Intuitive Surgical in July 2026.
Intuitive Surgical (ISRG) is the dominant name in robotic-assisted surgery, best known for its da Vinci surgical systems that enable minimally invasive procedures. With a sizeable installed base and recurring revenue from instruments, accessories and service contracts, the company has built a high-margin business that benefits as hospitals upgrade systems and expand robotic programmes. Key growth drivers include wider clinical adoption across specialties, new product introductions and expansion into less invasive procedures. Investors should weigh these opportunities against concentration risks — substantial reliance on a single product family, ongoing R&D spending, regulatory and reimbursement dynamics, and sensitivity to hospital capital budgets. Competition from established medical groups and new robotics entrants is rising. The market cap (~$165.9bn) reflects premium expectations of persistent growth and margin expansion; such expectations can reverse. This overview is educational and not investment advice — consider your risk tolerance and seek personalised guidance before acting.
Why It’s Moving
ISRG stays in focus as analysts lean on durable robotic surgery growth, not a new near-term shock.
- Analysts remain broadly constructive on Intuitive Surgical, with recent forecasts still implying notable upside, but the story is more about long-term procedure growth than a fresh catalyst in the past week.
- The latest commentary points to expectations that robotic surgery volume will keep expanding, which supports revenue durability and reinforces the company’s premium valuation.
- Recent analyst price-target updates show a wide range of views, suggesting investors are balancing strong platform momentum against execution risk and the stock’s already elevated expectations.
ISRG stays in focus as analysts lean on durable robotic surgery growth, not a new near-term shock.
- Analysts remain broadly constructive on Intuitive Surgical, with recent forecasts still implying notable upside, but the story is more about long-term procedure growth than a fresh catalyst in the past week.
- The latest commentary points to expectations that robotic surgery volume will keep expanding, which supports revenue durability and reinforces the company’s premium valuation.
- Recent analyst price-target updates show a wide range of views, suggesting investors are balancing strong platform momentum against execution risk and the stock’s already elevated expectations.
When is the next earnings date for INTUITIVE SURGICAL INC (ISRG)?
The next earnings date for ISRG is expected to be July 16, 2026, after the market closes. This report will cover Q2 2026 results. Some sources note the company has not formally confirmed the date, so it remains an estimated earnings release based on its usual reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Intuitive Surgical's stock, indicating strong potential for future growth.
Financial Health
Intuitive Surgical is generating strong revenue and cash flow, with healthy profit margins as well.
Dividend
Intuitive Surgical does not pay a dividend, which may indicate they are reinvesting profits to grow the business. If you invested $1000, you would receive $0 a year in dividends.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring ISRG
Global Medtech UAE Healthcare Investment Basket 2025
The United Arab Emirates is making significant investments to upgrade its medical infrastructure, aiming to become a global healthcare destination. This basket provides exposure to the international US and EU-listed companies in pharmaceuticals, medtech, and digital health that supply this ambitious national project.
Published: 12 November 2025
Explore BasketHealthcare Innovation Brazil Investment Theme 2025
Brazil is ramping up investment to enhance its healthcare quality and access, creating significant opportunities for innovation. This basket offers exposure to key US and EU-listed companies providing the medical devices, software, and biotech research driving this transformation.
Published: 30 October 2025
Explore BasketMedTech Stocks: Brazil Market Risks & Opportunities
Brazil's growing demand for advanced healthcare presents an opportunity to modernize its medical infrastructure and improve patient outcomes. This basket offers exposure to the leading US and European companies supplying Brazil with robotic surgery systems, AI diagnostics, and innovative medical devices.
Published: 21 October 2025
Explore BasketNiche Dominators
These carefully selected companies rule their specialized markets by design. They've built powerful competitive advantages in focused segments that larger companies often overlook, creating a path to consistent profits and sustainable growth.
Published: 17 June 2025
Explore BasketPatient Platforms
This carefully curated collection features companies building the technological foundations that will power innovation for decades to come. Our analysts have identified businesses creating essential infrastructure in genomics, AI, robotics, and advanced computing—platforms that could define their industries and generate substantial long-term returns.
Published: 17 June 2025
Explore BasketAI & Robotics Architects
Invest in companies that own the foundational patents powering our AI future. These carefully selected stocks represent firms whose intellectual property forms the blueprint for machine learning and automation, giving them a powerful competitive advantage for years to come.
Published: 17 June 2025
Explore BasketRestless Innovators
Companies that refuse to stand still, constantly pushing boundaries and redefining what's possible. These stocks have been carefully selected by our analysts for their relentless pursuit of innovation and potential for long-term growth.
Published: 17 June 2025
Explore BasketFuture Tech: World Changing Ideas
Get ahead of tomorrow's innovations with this collection of stocks pushing technological boundaries. Our analysts have carefully selected companies developing flying cars, breakthrough medical treatments, and robotic surgery that could reshape our future.
Published: 25 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue model
Consumables and service contracts create predictable follow-on sales, though hospital budgets and procedure volumes can affect revenue.
Innovation and R&D
Regular product updates and new platforms can open markets, but they require heavy R&D and face regulatory hurdles.
Global adoption trends
Growing use of minimally invasive surgery offers a large addressable market, yet adoption and reimbursement vary by region.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
